NCT04623216 2025-10-16Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.NovartisPhase 1/2 Terminated24 enrolled 16 charts